Arizona State Retirement System Trims Stock Position in Integer Holdings Co. (NYSE:ITGR)

Arizona State Retirement System lessened its holdings in Integer Holdings Co. (NYSE:ITGR) by 1.7% during the 4th quarter, Holdings Channel reports. The firm owned 9,311 shares of the medical equipment provider’s stock after selling 163 shares during the quarter. Arizona State Retirement System’s holdings in Integer were worth $923,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Covestor Ltd lifted its holdings in shares of Integer by 420.6% in the first quarter. Covestor Ltd now owns 328 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 265 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of Integer by 483.3% during the fourth quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 377 shares during the period. State of Wyoming lifted its stake in shares of Integer by 129.5% during the fourth quarter. State of Wyoming now owns 840 shares of the medical equipment provider’s stock valued at $58,000 after buying an additional 474 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Integer by 28.5% during the first quarter. Tower Research Capital LLC TRC now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 172 shares during the period. Finally, Point72 Middle East FZE purchased a new position in shares of Integer during the fourth quarter valued at approximately $96,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ITGR shares. KeyCorp upped their price objective on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research note on Tuesday, April 9th. CL King started coverage on shares of Integer in a research note on Thursday, March 14th. They set a “buy” rating and a $137.00 price objective on the stock. Benchmark upped their price objective on shares of Integer from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. Finally, Bank of America raised shares of Integer from a “neutral” rating to a “buy” rating and upped their price objective for the company from $105.00 to $135.00 in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Integer currently has an average rating of “Moderate Buy” and a consensus price target of $120.50.

Integer Stock Performance

NYSE:ITGR opened at $119.31 on Wednesday. The company has a quick ratio of 1.71, a current ratio of 2.80 and a debt-to-equity ratio of 0.64. The company has a market cap of $4.00 billion, a P/E ratio of 44.35, a P/E/G ratio of 1.46 and a beta of 1.10. Integer Holdings Co. has a fifty-two week low of $69.40 and a fifty-two week high of $121.53. The firm’s 50 day moving average is $111.09 and its two-hundred day moving average is $97.94.

Integer (NYSE:ITGR) last posted its quarterly earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.05. The company had revenue of $413.15 million for the quarter, compared to the consensus estimate of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. Integer’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.11 earnings per share. Analysts expect that Integer Holdings Co. will post 5.28 EPS for the current year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.